Higher doses of Zepbound to be offered on Eli Lilly website
See more sharing options
Send this page to someone via email
Share this item on Twitter
Share this item via WhatsApp
Share this item on Facebook
U.S. drugmaker Eli Lilly said on Monday it will offer the higher-dose versions of its popular weight-loss drug Zepbound on its website LillyDirect, with shipments starting in early August.
The company said the 12.5 milligrams and 15 mg doses of the drug will be available for US$499 per month on the website with shipments to self-paying patients.
1:27
Ozempic can lower chances of multiple health conditions but comes with risks, study finds
Healthcare providers can begin prescribing the 12.5 mg and 15 mg vials on July 7, the company added.
Story continues below advertisement
Lilly began offering vials of the two lowest doses of Zepbound, typically sold in auto-injector pens, in August last year.
In February, the company started offering the vials at a discount.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
2 days ago
- Globe and Mail
Novo Nordisk Stock (NVO) Inches Higher Despite More U.K. Weight Jab Concerns
Shares in pharmaceutical giant Novo Nordisk (NVO) edged higher today despite more pressure from health officials in the U.K. about the safety of weight-loss drugs. Confident Investing Starts Here: Pancreas Link The U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) said today that it will investigate whether there is a link between weight-loss injections and acute inflammation of the pancreas. Indeed, they are asking people on weight-loss drugs who have been hospitalized by acute pancreatitis to get in touch. This comes after data from MHRA which showed that since the drugs were licensed, there have been hundreds of reported cases of acute and chronic pancreatitis among people taking GLP-1 medicines. That includes 113 cases and one death linked to semaglutide, which is the active ingredient in Novo Nordisk's Wegovy and Ozempic weight-loss injections. Meanwhile, 181 cases, with five deaths, were reported linked to tirzepatide, which is the active ingredient in Eli Lilly's (LLY) rival Mounjaro treatment. MHRA chief safety officer Dr Alison Cave said the aim was to 'better predict those most at risk of adverse reactions.' Think Twice This follows a warning earlier this month from the MHRA to pregnant women that it is unclear whether weight-loss injections could harm unborn babies. Russ Mould, investment director at AJ Bell, said this regular commentary on the side effects of injectable weight-loss drugs could make some patients think twice about using them. 'Reports of pancreas-related illnesses in a tiny number of cases could yet attract regulatory scrutiny,' he added. In the UK, the injections are only available through the state-run National Health Service, but people are still accessing them via sellers on social media or beauty salons. The demand is expected to be there. Globally, about 3.8 billion people over 25 and just under 750 million children and young people will be overweight or obese by 2050. Is NVO a Good Stock to Buy Now? On TipRanks, NVO has a Moderate Buy consensus based on 4 Buy, 3 Hold and 1 Sell rating. Its highest price target is $142.56. NVO stock's consensus price target is $94.79 implying a 40.32% upside. See more NVO analyst ratings
Global News
3 days ago
- Global News
MHCare Medical calls for release of audit related to Alberta health contract allegations
See more sharing options Send this page to someone via email Share this item on Twitter Share this item via WhatsApp Share this item on Facebook An Alberta company swept up in allegations of government corruption says it's being further harmed by the suppression of a report it believes will exonerate them. Medical supply company MHCare Medical is calling on the province's front-line health provider to release an audit into health contracts commissioned by its former chief executive officer. MHCare believes the audit from former Alberta Health Services head Athana Mentzelopoulos may provide concrete proof allegations against its CEO are baseless. Mentzelopoulos is suing Premier Danielle Smith's government for wrongful dismissal, claiming she was fired for looking into questionable, overpriced contracts. 1:51 Alberta's auditor general says he needs extra funding for AHS probe MHCare is not named as a defendant in the lawsuit, but contracts it had with AHS were part of the examination by a law firm that is referenced in court documents. Story continues below advertisement The province has denied any wrongdoing, arguing in court documents that Mentzelopoulos was fired for poor job performance and for dragging her feet on health-care reforms. Get breaking National news For news impacting Canada and around the world, sign up for breaking news alerts delivered directly to you when they happen. Sign up for breaking National newsletter Sign Up By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy The contracts are the focus of three investigations, and MHCare says the repeated delays are unfair as the allegations tarnish their reputation and leave CEO Sam Mraiche with no chance to clear his name.
Global News
3 days ago
- Global News
Senator Patrick Brazeau recovering from ‘dizzy spell' that caused collapse
See more sharing options Send this page to someone via email Share this item on Twitter Share this item via WhatsApp Share this item on Facebook A Senate spokesman says Sen. Patrick Brazeau is recovering after a 'dizzy spell' made him 'briefly lose consciousness' Wednesday during debate in the Senate on the government's major projects bill. The 50-year-old Independent senator rose to speak before falling sideways to the floor just after 4 p.m. yesterday. Get breaking National news For news impacting Canada and around the world, sign up for breaking news alerts delivered directly to you when they happen. Sign up for breaking National newsletter Sign Up By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy The Senate spokesman says Brazeau was taken to Ottawa's Civic Hospital and returned home later that evening. The spokesman says Brazeau is 'recovering and in good spirits.' Brazeau was alert when paramedics came to help him in the Senate chamber Tuesday afternoon, says the spokesman. He added the senator is grateful to paramedics and hospital staff for their 'excellent' care.
